Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Metropolis Healthcare...

    Metropolis Healthcare gets SEBI nod, moves for Initial Public Offer

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-29T16:32:14+05:30  |  Updated On 29 Nov 2018 4:32 PM IST
    Metropolis Healthcare gets SEBI nod, moves for Initial Public Offer

    New Delhi: Metropolis Healthcare has received markets regulator Securities Exchange Board of India's (SEBI) approval to float initial public offerings. With this approval, Metropolis will be the fourth diagnostic company to look at an IPO after Dr Lal Pathlabs, Thyrocare Technologies and SRL Diagnostics have tapped the market.


    Metropolis Healthcare's IPO will see an offer for sale of up to 50,17,868 equity shares by Sushil Kanubhai Shah and up to 1,02,51,816 equity shares by CA Lotus Investments.


    JM Financial, Credit Suisse Securities (India), Goldman Sachs (India), HDFC BankNSE 1.22 % and Kotak Mahindra Capital Company are the managers to the issue.


    The Sebi's observations are necessary for any company to launch public issues such as initial public offer (IPO), follow-on public offer (FPO) and rights issue.


    Medical Dialogues had in September 2018 reported about Metropolis Healthcare filing its draft Red Herring Prospectus with market regulator SEBI for proposed to IPO (initial public offer). It had proposed IPO of over Rs 2000 crore


    Metropolis, under the leadership of Ameera Shah, has charted an aggressive growth and expansion path in the past 17 years. Metropolis is backed by private equity fund KKR and a Carlyle Private Equity portfolio company.


    With more than 4,500 employees, it has grown from 300 centres in FY 2015 to over 2,100 centres and 100-plus labs in FY2018. The company has 8,000 pick-up points from where it collects samples.


    In 2015, The Carlyle Group announced that an affiliate of Carlyle Asia Partners IV has bought a 37 per cent stake in Metropolis Healthcare Limited, a multinational chain of pathology laboratories. Carlyle acquired the stake held by Dr GSK Velu and his affiliates. The deal approximately cost Rs 900 crore


    The same year in April, the Shah family had raised its stake from 36 per cent to 63 per cent by acquiring 27 per cent from private equity firm Warburg Pincus for Rs 550 crore with the backing of KKR India.


    Read Also: Metropolis Healthcare to aim for Rs 2000 crore plus IPO: Report





    Ameera ShahapprovalCarlyleinitial public offerIPOKKRMetropolisMetropolis HealthcarepathlabpathologySEBI
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok